|
Inclusion criteria
|
Interview measures
| | | |
| |
Structured psychiatric interview (mini-dips)
|
x1
| | |
| |
Demographic and medical data
|
x
| | |
| |
Questionnaire measures
| | | |
|
Primary + Secondary Outcomes
|
Physical symptoms and side effects + coping (GASE+Coping)
|
x
| |
x
|
| |
Quality of life (EORTC QLQ C30 & BR23)
|
x
| |
x
|
| |
Adherence (MARS-D), Adherence Intention
|
x
|
x
|
x
|
|
Expectation Scales
|
Expected side effects + expected coping (GASE-Expect + * *Coping)
|
x
|
x
|
x
|
| |
Illness beliefs (IPQ-B)
|
x
|
x
|
x
|
| |
Beliefs about medicines (BMQ-D)
|
x
|
x
|
x
|
|
Process Variables
|
Fear of progression (PA-F-K)
|
x
|
x
|
x
|
| |
Anxiety and depression (HADS)
|
x
|
x
|
x
|
| |
Knowledge hormone receptor
|
x
|
x
|
x
|
| |
Treatment evaluation
| |
x2
| |
|
Control Variables
|
Somatosensory amplification (SSAS)
|
x
| | |
| |
Prior experiences with endocrine treatment
|
x
| | |
| |
Partnership quality
|
x
| | |
| |
Additional medication
|
x
| |
x
|
